Telix Pharmaceuticals Ltd — Share Issue/Capital Change 2024

Sep 10, 2024

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Announcement Summary

Entity name

TELIX PHARMACEUTICALS LIMITED

Date of this announcement

Wednesday September 11, 2024

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securities to be issued/transferred

		Total number of
ASX +security		+securities to be
code	Security description	issued/transferred	Issue date
TLXAP	SHARE RIGHTS	260,000	09/09/2024

Refer to next page for full details of the announcement

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

1 / 7

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 1 - Entity and announcement details

1.1 Name of entity

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type Registration number ACN 616620369

1.3 ASX issuer code

TLX

1.4 The announcement is

New announcement

1.5 Date of this announcement

11/9/2024

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

2 / 7

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

3 / 7

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description TLXAP : SHARE RIGHTS Date the +securities the subject of this notification were issued 9/9/2024 Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes Were any of the +securities issued to +key management personnel (KMP) or an +associate? Yes Provide details of the KMP or +associates being issued +securities. Name of KMP Name of registered holder Number of +securities Darren Patti Darren Patti 15,000 Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms - - Refer to Telix Equity Incentive Plan Rules accessible at https://telixpharma.com/investor centre/corporate governance/ ap proved at AGM held 22 May 2024. Notice of Meeting with summary of amended EIP terms accessible at https://telixpharm a.com/news-views/notice-of-annual-general-meeting-2024/. Any other information the entity wishes to provide about the +securities the subject of this notification Tranche 3 of 2022 retention rights grant to certain Telix employees: - Share rights @ zero exercise price, 100% maximum vesting subject to service conditions being met and individual performance - Total number granted: 130,000 (including 15,000 granted to Darren Patti, who transitioned to Group Chief Operating Officer and KMP effective 11 March 2024) - Performance period: 1 January 2024 to 31 March 2025 - Testing/vesting date: April 2025 - Exercise period: all employees (excluding US): 2 years from the vesting date. For US employees: auto-exercise on 1 April 2025

Issue details

Number of +securities 130,000

ASX +security code and description

TLXAP : SHARE RIGHTS

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

4 / 7

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Date the +securities the subject of this notification were issued

9/9/2024

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate? No

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

• • Refer to Telix Equity Incentive Plan Rules accessible at https://telixpharma.com/investor centre/corporate governance/ ap proved at AGM held 22 May 2024. Notice of Meeting with summary of amended EIP terms accessible at https://telixpharm a.com/news-views/notice-of-annual-general-meeting-2024/.

Any other information the entity wishes to provide about the +securities the subject of this notification

2023 retention rights grant to certain Telix employees:

• Share rights @ zero exercise price, 100% maximum vesting subject to service conditions being met and individual performance

• Total number granted: 130,000 over two tranches - Performance period: Tranche 1 (65,000 share rights) 1 January 2024 to 31 March 2027; Tranche 2 (65,000 share rights) 1 January 2024 to 31 March 2028

• Testing/vesting date: Tranche 1 - 1 April 2027; Tranche 2 - 1 April 2028 - Exercise period: all employees (excluding US): 2 years from the vesting date. For US employees: auto-exercise on 1 April 2027 (Tranche 1) and 1 April 2028 (Tranche 2)

Issue details

Number of +securities

130,000

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

5 / 7

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

	Total number of
ASX +security code and description	+securities on issue
TLX : ORDINARY FULLY PAID	334,652,216
4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)
	Total number of
ASX +security code and description	+securities on issue
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAR : PERFORMANCE RIGHTS	6,807,720
TLXAP : SHARE RIGHTS	1,475,000
TLXAO : SHARE APPRECIATION RIGHTS	10,776,459
TLXAT : CONVERTIBLE NOTES	3,250
TLXAM : OPTION EXPIRING 20-JUL-2026 EX $5.37	479,992
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAL : OPTION EXPIRING 27-JAN-2026 EX $4.38	673,718
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

6 / 7

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

7 / 7